Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

What happened: Global cancer medicine spending reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, per the IQVIA Institute, with the U.S. at roughly 46% of the total. Gastrointestinal cancers are drawing growing research attention. Key numbers: $252 billion spent in 2024; forecast above $400 billion by 2028; U.S. Why it matters: The content says the pipeline is turning into new standards of care, citing recent FDA approvals and positive Phase 3 results, with colorectal cancer updates expected before year-end and the ESMO 2026 Congress in Madrid from October 23 to 27. Market: +2.5% today ($60.99), +39.9% YTD, 1.2x vol — as of 23:00 UTC Coverage: 3 outlets in 24h

Global cancer medicine spending reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, per the IQVIA Institute, with the U.S. at roughly 46% of the total. Gastrointestinal cancers are drawing growing research attention.

The content says the pipeline is turning into new standards of care, citing recent FDA approvals and positive Phase 3 results, with colorectal cancer updates expected before year-end and the ESMO 2026 Congress in Madrid from October 23 to 27. Market: +2.5% today ($60.99), +39.9% YTD, 1.2x vol — as of 23:00 UTC